Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
VentriPoint Diagnostics ( (TSE:VPT) ) has shared an update.
Ventripoint Diagnostics has entered a collaboration with the Health Division of Costa Rica’s Montecristo Group to explore deploying its VMS+ AI-assisted cardiac imaging platform across the country’s healthcare network. The initiative targets both public and private providers, with an emphasis on remote and underserved communities, to expand access to advanced cardiac diagnostics and improve accuracy in monitoring congenital and structural heart disease.
The partnership includes plans to integrate VMS+ into clinical research, large-scale screening, and clinical trial programs, positioning the system as an affordable tool to support new models of cardiovascular care. By leveraging Montecristo’s Metropolitano Research Institute as a research partner, the collaboration is expected to enhance early detection, strengthen research capabilities, and support broader adoption of AI-driven echocardiography in Central America.
The most recent analyst rating on (TSE:VPT) stock is a Hold with a C$0.12 price target. To see the full list of analyst forecasts on VentriPoint Diagnostics stock, see the TSE:VPT Stock Forecast page.
Spark’s Take on VPT Stock
According to Spark, TipRanks’ AI Analyst, VPT is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, cash burn, and negative equity). Technicals are moderately constructive with improving momentum, and corporate updates are directionally positive, but valuation support is limited due to negative earnings and no dividend indicated.
To see Spark’s full report on VPT stock, click here.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. is a Canadian medical technology company specializing in AI-assisted cardiac imaging, led by its VMS and VMS+ platforms that use proprietary Knowledge Based Reconstruction to generate MRI-equivalent volumetric heart measurements from echocardiograms. Its products are designed as affordable, vendor-agnostic tools that integrate with ultrasound systems and hold regulatory approvals in the U.S., Europe, and Canada, targeting improved cardiac diagnostics for cardiologists and healthcare systems.
Average Trading Volume: 101,414
Technical Sentiment Signal: Sell
Current Market Cap: C$22.52M
Learn more about VPT stock on TipRanks’ Stock Analysis page.